Gatipotuzumab is another mAb used in phase I/II clinical trials for solid tumors (NCT03360734, NCT01222624) that binds to STn-bearing MUC1 and prevents its interactions with siglec-9, to instigate ADCC against the tumor cells (57, 58). Here, MUC1 is linked to neoplasm.